Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of IFN-gamma Primed MSCs in Asthma
NCT05035862Phase 1Terminated
- Sponsor
- Emory University
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of interferon gamma-primed mesenchymal stromal cells in asthma, sponsored by Emory University. Primary endpoints: Change in number of adverse events and severe adverse events post-intervention and Number of grade >=3 adverse reaction attributable to the γMSC product. Started Mar 2022; status: terminated.
02
Drugs
interferon gamma-primed mesenchymal stromal cells
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05035862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035862.